[Clinico-theoretical considerations on the association of trifluoperazine and coronary vasoactive drugs in the treatment of anxiety states in aged cardiopathic patients].
D001007:Anxiety / Q000188:drug therapy*; D001008:Anxiety Disorders / Q000188:drug therapy*; D006331:Heart Diseases / Q000150:complications*; D006801:Humans; D010208:Papaverine / Q000627:therapeutic use*; D010417:Pentaerythritol Tetranitrate / Q000627:therapeutic use*; D010640:Phenothiazines / Q000627:therapeutic use; D014149:Tranquilizing Agents / Q000627:therapeutic use; D014268:Trifluoperazine / Q000627:therapeutic use*
D010640:Phenothiazines; D014149:Tranquilizing Agents; D010417:Pentaerythritol Tetranitrate; D014268:Trifluoperazine; D010208:Papaverine
Considerazioni clnico-teoriche circa l'associazione trifluoperazina-vasocoronaroattivi nel trattamento degli stati d'ansia dei senili cardiopatici.